LUCIDITY phase 3 topline data presented at CTAD for HMTM – the...
- Written by LATEST ASIANET NEWS RELEASES
- Published in Asia Net
ABERDEEN, Scotland and SINGAPORE, Nov. 30, 2022 /PRNewswire-AsiaNet/ -- - Tau aggregation inhibitor, HMTM, is an oral drug with a strong safety profile, having no risk of amyloid related imaging abnormalities- Topline results for the Phase 3 study, LUCIDITY, were shared at the Clinical Trials in Alzheimer's Diseas...
Authors: LATEST ASIANET NEWS RELEASES